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Abstract 
Background: Two common single nucleotide polymorphisms within the COL5A1 gene 
(SNPs; rs12722 C/T and rs3196378 C/A) have previously been associated with tendon and 
ligament pathologies. Given the high incidence of tendon and ligament injuries in elite rugby 
athletes, we hypothesised that both SNPs would be associated with career success. 
 
Methods: In 1105 participants (RugbyGene project), comprising 460 elite rugby union (RU), 
88 elite rugby league athletes and 565 non-athlete controls, DNA was collected and genotyped 
for the COL5A1 rs12722 and rs3196378 variants using real-time PCR. 
 
Results: For rs12722, the injury-protective CC genotype and C allele were more common in 
all athletes (21% and 47%, respectively) and RU athletes (22% and 48%) than in controls (16% 
and 41%, P ≤ 0.01). For rs3196378, the CC genotype and C allele were overrepresented in all 
athletes (23% and 48%) and RU athletes (24% and 49%) compared with controls (16% and 
41%, P ≤ 0.02). The CC genotype in particular was overrepresented in the back and centres 
(24%) compared with controls, with more than twice the odds (OR = 2.25, P = 0.006) of 
possessing the injury-protective CC genotype. Furthermore, when considering both SNPs 
simultaneously, the CC–CC SNP-SNP combination and C–C inferred allele combination were 
higher in all the athlete groups (≥ 18% and ≥ 43%) compared with controls (13% and 40%; P 
= 0.01). However, no genotype differences were identified for either SNP when RU playing 
positions were compared directly with each other. 
 
Conclusion: It appears that the C alleles, CC genotypes and resulting combinations of both 
rs12722 and rs3196378 are beneficial for rugby athletes to achieve elite status and carriage of 
these variants may impart an inherited resistance against soft tissue injury, despite exposure to 
the high-risk environment of elite rugby. These data have implications for the management of 
inter-individual differences in injury risk amongst elite athletes.  
Background 
Elite rugby athletes regularly experience high velocity collisions that lead to increasingly high 
injury occurrence rates that are likely to be a consequence of the increasing size and strength 
of the athletes [1-4]. This increased size and strength is likely to result in greater changes in 
momentum during player collisions, as well as during voluntary accelerations and 
decelerations. This has resulted in rugby union (RU) having one of the highest reported injury 
incidence rates in professional team sports [5]. Meta-analyses have shown that for every 1000 
hours, an elite RU athlete will experience approximately 81 injuries during match play and 
three during training, with the majority being ligament, tendon and muscle injuries of the lower 
limbs [6]. Indeed, in the most recent Rugby World Cup (2015) this rate of incidence was more 
than 90 injuries per 1000 h [7]. Furthermore, pooled data from 10 studies of elite rugby league 
(RL) athletes show that injury incidence is approximately twice (172 per 1000 h) that of RU 
[8]. Similar to RU, the majority of injuries in RL occur on the lower limbs, consisting mainly 
of sprains and strains [8]. Furthermore, injury incidence differs across RU playing position, 
with elite back row players showing the highest rate among forwards and centres the highest 
among backs [7]. Therefore, investigating the molecular genetic components of these injuries, 
including in the context of playing positions that differ in terms of physiological characteristics 
[9, 10], match play demands [11] as well as genetically [12], may progress understanding 
towards greater individualisation of match play exposure and training load and mode, in order 
to reduce injury risk [13]. 
 
The collagen fibril, which consists predominately of type I collagen, is the primary structural 
component of tendons, ligaments and other non-cartilaginous connective tissues [14]. The 
formation and diameter of the collagen fibril is regulated by, amongst other molecules, the 
minor fibrillar type V collagen protein, which forms between 1-5% of total collagen content of 
connective tissue [15-18]. The type V collagen isoform comprises two α1(V) and one α2(V) 
chains, encoded by the COL5A1 and COL5A2 genes respectively [16, 19] and forms between 
1-5% of total collagen content [18, 20]. The COL5A1 gene is the most explored genetic locus 
in relation to tendon and ligament injuries [21-25], while mutations in the COL5A1 gene have 
been identified in Ehlers-Danlos syndrome, a disease characterised by joint hypermobility, 
laxity and muscle hypotonia [26]. This results in irregularly large collagen fibrils within 
connective tissue [27] and is attributed to a reduced synthesis of collagen type V [17, 28]. 
 
Two common single nucleotide polymorphisms (SNPs, rs12722 C/T and rs3196378 C/A) 
located in the functional 3′ untranslated region (3′ UTR) COL5A1 gene on chromosome 9 have 
been associated with tendon [23] and ligament [rs12722; 29] injuries. Specifically, the CC 
genotype of the more extensively investigated rs12722 polymorphism has been previously 
associated with reduced risk of chronic Achilles tendinopathy [odds ratio (OR) = 0.42-AUS 
and OR = 0.38-SA, OR = 2.6, respectively; 23, 25], anterior cruciate ligament injury in females 
[OR = 6.6; 22] and lateral epicondylitis [OR = 1.4; 21], suggesting a protective role of the C 
allele against injury. Although there are conflicting results [23, 30], our current understanding 
also suggests that the CC genotype and/or the C allele of rs3196378 would also have a 
protective role [31, 32]. Considering the high frequencies of tendon and ligament inquiries in 
elite rugby [6-8, 33], assessing these specific genetic variants may be of use in helping improve 
the management of injury risk in individual players. 
 
Given the association of the two COL5A1 gene variants with injury risk, it is possible that 
possession of the risk alleles might reduce an individual’s ability to withstand exposure to the 
environment of competitive rugby without suffering more frequent injuries. Consequently, 
those individuals would be forced to miss training, selection and competitive events important 
for their career progression. Thus, athletes carrying the C allele at either or both rs12722 and 
rs3196378 might be at an advantage in terms of their ability to achieve success in elite 
competitive rugby and at a disadvantage in terms of their shorter-term and longer-term 
musculoskeletal health. Therefore, the objective of the present study was to investigate if 
COL5A1 rs12722 and rs3196378 genotype and allele frequencies differed between elite rugby 
athletes and a control population, and/or between playing positions. It was hypothesised that 
the COL5A1 rs12722 and rs3196378 injury-protective C alleles and/or CC genotypes would be 
overrepresented in elite rugby athletes compared with controls. 
 
Methods 
Participants 
As part of the ongoing RugbyGene project [12, 13, 34], a total of 1105 individuals were 
recruited and gave written informed consent to participate in the present study. An a priori 
calculation for 80% power to detect a small effect size (w) of 0.1 required a sample of >785 
participants. The sample comprised elite Caucasian male rugby athletes (n = 540; mean 
(standard deviation) height 1.85 (0.07) m, mass 101 (14) kg, age 29 (7) years) including 72% 
British, 16% South African, 7% Irish and 5% of other nationalities. Caucasian controls (68% 
male; n = 565; height 1.75 (0.10) m, mass 75 (13) kg, age 26 (11) years) included 86% British, 
12% South African, 1% Irish and 1% of other nationalities recruited mainly during 2012-2016. 
Eight athletes competed in both elite RL and RU and were included in both groups that were 
analysed separately. Athletes were considered elite if they had competed regularly (> 5 
matches) since 1995 in the highest professional league in the UK, Ireland or South Africa for 
RU and the highest professional league in the UK for RL. Of the RU athletes, 51.7% had 
competed at international level for a “High Performance Union” (Regulation 16, 
worldrugby.org) and 43.2% of RL had competed at international level. All data for the athlete 
group’s international status were confirmed as of 1st January 2017. Most participants in the 
current study were also participants in previous publications regarding variations in the ACTN3, 
ACE and FTO genes [12, 34]. 
 
Sample collection and genotyping 
Description of all molecular procedures have previously been described in detail [12]. Briefly, 
blood (~70% of all samples), saliva (~25%) or buccal swab samples (~5%) were obtained via 
the following protocols. Blood from a superficial forearm vein was put into an EDTA tube and 
stored in sterile tubes at -20°C until processing. Saliva samples were collected using Oragene 
DNA OG-500 collection tubes (DNA Genotek Inc., Ontario, Canada) according to the 
manufacturer’s protocol and stored at room temperature until processing. Sterile buccal swabs 
(Omni swab, Whatman, Springfield Mill, UK) were rubbed against the buccal mucosa of the 
cheek for approximately 30 s and the tips stored at -20°C until processing. At MMU and 
Glasgow, DNA was stored at 4°C following isolation performed using the QIAamp DNA Blood 
Mini kit and standard spin column protocol (Qiagen, West Sussex, UK). In Cape Town, DNA 
was isolated from whole blood [35] and samples stored at -20°C. At Northampton, DNA was 
isolated from whole blood using Flexigene kits (Qiagen), with the resulting samples stored at 
-20°C. 
 
Genotyping at all three centres was performed using TaqMan assays (Applied Biosystems, 
Paisley, UK) for both the COL5A1 rs12722 and rs3196378 variants. Our genotyping methods 
and quality control procedures have been fully described in our earlier study [12]. Minor 
adaptations were made to the volumes used in each assay mix depending on whether the DNA 
was obtained from buccal swabs or saliva/blood. PCR was performed on either a Chromo4 
(Bio-Rad, Hertfordshire, UK) or StepOnePlus thermal cycler (Applied Biosystems). Genotypes 
were called based on reporter dye intensity and visualized using cluster plots. The TaqMan 
assays included VIC and FAM dyes that for rs12722 indicated C and T alleles on the forward 
DNA strand, respectively. Thus, VIC/FAM were interpreted as: 5′-
CACACCCA[C/T]GCGCCCCG-3′. For rs3196378, VIC and FAM dyes indicated C and A 
alleles on the forward DNA strand, respectively and were interpreted as: 5′-
CCCACCCC[A/C]GCCCTGGC-3′. Genotype calling was 100% successful for both 
polymorphisms in the athlete samples. For rs12722, one of the 566 control samples was 
unsuccessful and, for rs3196378, 10 of the 566 control samples were unsuccessful. There was 
100% agreement among reference samples genotyped in the three genotyping centres, i.e. 
Glasgow, Northampton and MMU laboratories. 
 
Data analysis 
SPSS for Windows version 22 (SPSS Inc., Chicago, IL) software was used to conduct 
Pearson’s Chi-square (χ2) tests to compare genotype (using three analysis models; additive, 
recessive and dominant), allele and inferred haplotype frequencies between athletes and 
controls, and between RU subgroups based on playing position and controls. With 80% 
statistical power, analyses of all genetic models in positional subgroups compared with controls 
(forwards, backs and back 3-centres) were able to detect a small-to-medium effect size (w) of 
0.12. Multifactor Dimensionality Reduction (MDR; 
www.multifactordimensionalityreduction.org) software was used to calculate SNP-SNP 
epistasis interactions [36]. Haplotypes were inferred using SNPStats [37]. Sixty five tests were 
subjected to Benjamini-Hochberg [BH; 38] corrections to control false discovery rate and 
corrected probability values are reported. Odds ratios (OR) were calculated to estimate effect 
size. CubeX online software (www.oege.org/software/cubex) was used to determine linkage 
disequilibrium statistics [39]. Alpha was set at 0.05. 
 
Results 
Genotype frequencies were in Hardy-Weinberg equilibrium for both rs12722 and rs3196378 
in the control (P ≥ 0.21) and athlete groups (RL, P ≥ 0.11; RU, P ≥ 0.754). There was no sexual 
dimorphism of genotype frequency for either rs12722 (P = 0.279) or rs3196378 (P = 0.374) 
within the control group. COL5A1 rs12722 and rs3196378 were in tight linkage disequilibrium 
for both controls (D′ = 0.902, r2 = 0.784) and all athletes (D′ = 0.877, r2 = 0.738). Athletes were 
taller and heavier (P < 0.05) but not older (P > 0.05) than controls. 
 
rs12722 
The CC genotype, proportion of C allele carriers and C allele were overrepresented in all 
athletes (21.1%, 73.3% and 47.2%, respectively) and RU athletes (22.0%, 73.3% and 47.6%) 
compared with controls (15.6%, 66.5% and 41.1%, Table 1 and Figure 1, P ≤ 0.01). 
Furthermore, the CC genotype, proportion of C allele carriers (Table 1) and C allele (Figure 1) 
were overrepresented in the subgroups of RU forwards (22.1%, 71.5% and 46.8%) and backs 
(21.8%, 75.6% and 48.7%) compared with controls (15.6%, 66.5% and 41.1%). Additionally, 
of the RU subgroups, the back three and centres differed from controls and showed the greatest 
C allele and CC genotype frequency (50.8% versus 41.1% and 24.4% versus 15.6%, 
respectively, Table 1 and Figure 1, P ≤ 0.02). Compared with controls, those back three and 
centre players had 2.3 times the odds of possessing the CC genotype and 1.5 times the odds of 
possessing the C allele (Table 2).  
 
<INSERT Table 1 and Table 2 HERE> 
 
rs3196378 
The CC genotype, proportion of C allele carriers and C allele were overrepresented in all 
athletes (23.1%, 73.3% and 48.4%) and RU athletes (23.9%, 73.3% and 48.6%) compared with 
controls (15.6%, 67.7% and 41.4%, Table 1 and Figure 1, P ≤ 0.02). Furthermore, CC 
genotype, proportion of C allele carriers (Table 1) and C allele (Figure 1) were overrepresented 
in backs (21.8%, 75.1% and 48.5%) compared with controls (15.6%, 67.7% and 41.4%, P ≤ 
0.02). Forwards also had higher CC genotype and C allele frequencies (25.5% and 48.7%; 
Table 1 and Figure 1) and showed almost twice the odds of being CC genotype than carrying 
an A allele, compared with controls (Table 2). For the back three and centres group, 24.4% 
were CC genotype, 77.2% were C allele carriers and C allele frequency was 47.8% - all of 
which were greater than controls (P ≤ 0.02; Table 1 and Figure 1, OR = 2.25, Table 2).  
 
Haplotype and SNP epistasis analysis 
There was a greater frequency of the CC–CC SNP-SNP combination in all athletes (18.3%), 
RU athletes (18.9%), RU forwards (19.4%), RU backs (18.3%) and to the greatest extent the 
back three and centre group (20.3%; OR = 2.35; Table 2), compared with control (12.8%; all 
athlete comparisons with the control group were P = 0.01). Furthermore, C–C inferred 
haplotype frequencies were higher in all the athlete groups compared with controls, reflected 
by a greater frequency of the T–A inferred haplotype in the control group (P = 0.01; Figure 2). 
 
Discussion 
The present observations are the first to identify associations between COL5A1 rs12722 and 
rs3196378 polymorphisms and athlete status in a large cohort of elite rugby athletes. As 
hypothesised, the apparent injury-protective C allele and CC genotype, of both SNPs [23], were 
overrepresented in elite rugby athletes compared with controls. This association persisted 
across playing position, with the C allele being overrepresented in RU forwards and backs 
including the back three and centres group, compared with controls. Furthermore, when the 
two SNPs are combined, the CC–CC combination and C–C inferred allele combination showed 
similar overrepresentation in elite rugby athletes compared with controls. 
 
The results provide an insight into the potential injury susceptibility of some elite rugby 
athletes. September et al. [23] identified a higher frequency of the CC genotype in 
asymptomatic controls for both rs12722 and rs3196378 compared with tendinopathy patients 
[23, 32]. Moreover, the rs12722 T allele has been associated with ligament injury [21, 22, 24, 
40] and Achilles tendinopathy [23, 25] with the C allele again identified as protective in these 
studies, despite a lack of replication in another study [30]. Greater joint laxity has almost a 3-
fold increase in risk of knee ligament rupture [41] and greater joint laxity has recently been 
associated with the rs12722 T allele in non-white females [40]. Collectively, these data suggest 
that the C allele of rs12722 and/or rs3196378 (or other variant(s) in strong LD with these SNPs) 
might be beneficial in protecting against tendon and ligament injuries. This is reflected in the 
present study showing greater C allele frequency in elite rugby athletes compared with controls. 
Based on these data, we propose that when exposed to the high-risk environment of rugby 
during training and especially during competitive matches, ceteris paribus, carriage of the C 
alleles at the rs12722 and rs3196378 loci provides both a shorter-term and longer-term 
advantage to rugby athletes in the form of reduced injury risk. Athletes with fewer and/or less 
severe injuries, all else being equal, will miss fewer matches, training and selection events and 
thus be more likely to progress towards elite status in their athletic careers compared with their 
peers. 
 
The rs12722 CC genotype has also been related to a lower incidence of exercise-associated 
muscle cramping (EAMC) in Caucasian ironman and ultra-marathon athletes [42]. The authors 
hypothesised that this was due to similar mechanisms of reduced tendon injury susceptibility, 
in that rs12722 alters soft tissue structural and mechanical properties (tissue stiffness and 
thickening). Some recent findings might support this hypothesis, as greater tendon stiffness 
was associated with the rs12722 T allele in one study [43], however another study reported no 
association of rs12722 with tendon structural or mechanical properties [44]. These data suggest 
that in addition to the apparent protection from tendon and ligament injury, the greater 
frequencies of the C allele in elite rugby athletes might be protective against muscle cramping 
and possibly reduced tendon stiffness. Indeed, recent evidence from elite RL shows that over 
70% of athletes experience EAMC per season and that history of cramping is the strongest 
predictor of future EAMC [45]. In contrast, the TT genotype has been associated with greater 
endurance running ability of Caucasian ironman triathletes [TT = 294 min, CC = 307 min; 46]. 
However, recent data show no association of rs12722 with either  running economy or VȮ2max 
[47]. While endurance capacity is of value in elite rugby, the predominant focus of player 
selection and training programs is towards power, speed and strength - i.e. short-term, 
anaerobic performance [with notable differences between playing positions; 9, 10]. 
 
Limited data exist regarding COL5A1 genetic variation and team sport athletes. In a study of 
73 soccer athletes, including some elite players, no rs12722 TT genotype individuals were 
identified (a potentially interesting observation but difficult to interpret because of the varied 
geographic ancestry of the athletes), but there was a tendency for more severe muscle injuries 
in the TC genotype group (P = 0.08), compared with CC [48]. Here, consistent with those 
observations, we show an overrepresentation of the protective C allele and CC genotype of 
both rs12722 and rs3196378, in addition to CC–CC SNP-SNP combination and C–C inferred 
allele combination in elite rugby athletes. 
 
Some possible mechanisms have been proposed to explain the association of COL5A1 gene 
variants and soft tissue injury [31, 32]. Laguett et al. [32] have shown that the COL5A1 3′ UTR 
– where both rs12722 and rs3196378 are situated - affects mRNA stability. For both SNPs, the 
alleles associated with greater soft-tissue injury risk were associated with greater Hsa-miR-608 
stability, which in turn may alter the Col5α1 protein secondary structure - proposed to play a 
role in type V collagen production [31]. This would suggest that C/T allele differences at 
rs12722 might alter the co-polymerisation of collagen type V and type I fibrils. However, to 
date, this has not been demonstrated experimentally and exactly how this may translate into 
functional properties is currently unknown. Nevertheless, it appears that the C allele and CC 
genotype of rs12722 and rs3196378 appear beneficial for rugby athletes to achieve elite status, 
probably through greater resistance to soft tissue injury. Interestingly, while most relevant 
investigations have focussed on rs12722, we show in a large cohort (total n = 1090) that strong 
linkage disequilibrium exists in both controls and athletes between rs12722 and rs3196378. As 
such, it is likely that the associations of rs12722 with tendon and ligament injuries would be 
similar for rs3196378. It is possible that combining genetic data from multiple gene variants 
associated with injury susceptibility, such as those presented here, with other indicators of 
injury risk and recovery during rehabilitation could be used to better manage the prevention 
and recovery from elite player injury in the future. 
 
In conclusion, we have presented the first associations between COL5A1 3′ UTR rs12722 and 
rs3196378 and elite status within a large cohort of rugby athletes. The C alleles of both 
polymorphisms, separately and in combination, were overrepresented in all athletes, RU 
forwards, backs and in RU back three and centre players versus controls. We propose that 
rugby athletes possessing more C alleles at these two genetic loci are probably at a lower risk 
of injury, given their exposure to the high-risk environment of elite rugby. However, these data 
pertain to only two SNPs of many that may be relevant to soft tissue injury and interpretation 
of the present results should be in that context. Future investigations should seek to combine 
elite rugby genotype data such as these with injury incidence data during rugby matches and 
training. It will be important to establish whether inter-individual differences in injury risk, 
within a population that we demonstrate here appear to be at an overall lower genetic risk of 
tendon and ligament injury compared with non-athletes, nevertheless are associated with those 
same genetic loci. 
 
Abbreviations: RU, rugby union; RL, rugby league; COL5A1, collagen type V α1; COL5A2, 
collagen type V α2; SNP, single nucleotide polymorphisms; 3′ UTR, 3′ untranslated region; 
EDTA, ethylenediaminetetraacetic acid; DNA, deoxyribonucleic acid; PCR, Polymerase chain 
reaction; MDR, multifactor dimensionality reduction; EAMC, exercise-associated muscle 
cramping; miRNA, micro ribonucleic acid. 
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Figure 1 Allele frequency of COL5A1 rs12722 (A) and rs3196378 (B) for control and athlete 
groups. Asterisks indicate a difference in allele frequency between the particular athlete group 
and controls. A single asterisk (*) designates P = 0.01 and a double asterisk (**) designates P 
= 0.02. RU, rugby union, RL rugby league. Eight athletes competed in both elite RL and RU 
and were included in both groups that were analysed separately. 
 
Figure 2 Inferred haplotype frequencies derived from COL5A1 rs12722 and rs3196378. RU, 
rugby union. Asterisks (*) indicate differences in inferred haplotype frequencies between the 
controls and each athlete group (P = 0.01). Eight athletes competed in both elite RL and RU 
and were included in both groups that were analysed separately. 
  
 
Table 1 COL5A1 rs12722 and rs3196378 genotype and allele distribution of controls and athletes separated by code (RL and RU) 
and into positional sub-groups for RU, presented as genotype/allele counts followed by percentage in parentheses. 
Genotype Controls All athletes RL athletes RU athletes Forwards Backs 
Back 3 and 
Centres 
rs12722        
      TT 189 (33.4) 144 (26.7) 23 (26.1) 123 (26.7) 75 (28.5) 48 (24.4) 28 (22.8) 
      CT 288 (51.0) 282 (52.2) 51 (58.0) 236 (51.3) 130 (49.4) 106 (53.8) 65 (52.8) 
      CC 88 (15.6) 111 (21.1)* 14 (15.9) 101 (22.0)* 58 (22.1)* 43 (21.8)* 30 (24.4)* 
Total 565 540 88 460 263 197 123 
T allele carriers 477 (84.4) 426 (78.9)* 74 (84.1) 359 (78.0)* 205 (77.9)* 154 (78.2)* 93 (75.6)* 
C allele carriers 379 (66.5) 396 (73.3)* 65 (73.9) 337 (73.3)* 188 (71.5) 149 (75.6)* 95 (77.2)* 
rs3196378        
      AA 183 (32.9) 144 (26.7) 23 (26.1) 123 (26.7) 74 (28.1) 49 (24.9) 28 (22.8) 
      CA 286 (51.4) 271 (50.2) 49 (55.7) 227 (49.3) 122 (46.4) 105 (53.3) 65 (52.8) 
      CC 87 (15.6) 125 (23.1)* 16 (18.2) 110 (24.0)* 67 (25.5)* 43 (21.8) * 30 (24.4)* 
Total 556 540 88 460 263 197 123 
A allele carriers 469 (84.4) 415 (76.9)* 72 (81.8) 350 (76.1)* 196 (74.5)* 154 (78.2)* 93 (75.6)* 
C allele carriers 373 (67.1) 396 (73.3)* 65 (73.9) 337 (73.3)* 189 (71.9) 148 (75.1)* 95 (77.2)* 
RU, rugby union, RL rugby league. The genotype, T allele carrier and C allele carrier data represent the additive, dominant model 
and recessive models, respectively. Eight athletes competed in both elite RL and RU and were included in both groups that were 
analysed separately. 
Asterisks (*) indicate Chi-square differences from controls (P ≤ 0.03).
Table 2 Odds ratio statistics for RU player status of COL5A1 gene variants 
(rs12722 and rs3196378). 
Positional comparison  Model †Odds 
Ratio 
95% Confidence 
Interval 
rs12722    
All athletes v Controls CC/TT 
CC/Tcarriers 
Callele/Tallele 
1.70 
1.45 
1.28 
1.19-2.42 
1.07-1.97 
1.08-1.52 
RU athletes v Controls CC/TT 
CC/Tcarriers 
Callele/Tallele 
1.76 
1.53 
1.30 
1.22-2.54 
1.11-2.09 
1.09-1.55 
Forwards v Controls CC/TT 
CC/Tcarriers 
Callele/Tallele 
1.66 
1.53 
1.26 
1.08-2.54 
1.06-2.22 
1.02-1.55 
Backs v Controls CC/TT 
CC/Tcarriers 
Callele/Tallele 
1.92 
1.51 
1.36 
1.19-3.12 
1.01-2.27 
1.08-1.72 
Back 3 and centres v 
Controls 
CC/TT 
CC/Tcarriers 
Callele/Tallele 
2.30 
1.76 
1.48 
1.29-4.08 
1.09-2.78 
1.12-1.96 
rs3196378    
All athletes v Controls CC/AA 
CC/Acarriers 
Callele/Aallele 
1.83 
1.66 
1.32 
1.29-2.59 
1.22-2.25 
1.12-1.56 
RU athletes v Controls CC/AA 
CC/Acarriers 
Callele/Aallele 
1.88 
1.73 
1.34 
1.31-2.70 
1.27-2.37 
1.12-1.59 
Forwards v Controls CC/AA 
CC/Acarriers 
Callele/Aallele 
1.90 
1.88 
1.34 
1.25-2.89 
1.31-2.69 
1.09-1.66 
Backs v Controls CC/AA 
CC/Acarriers 
Callele/Aallele 
1.85 
1.54 
1.33 
1.14-2.99 
1.02-2.31 
1.06-1.68 
Back 3 and centres v 
Controls 
CC/AA 
CC/Acarriers 
Callele/Aallele 
2.25 
1.78 
1.46 
1.27-4.00 
1.11-2.84 
1.11-1.93 
Haplotypes and SNP epistasis  
All athletes v Controls C–C/T–A 
*CC–CC 
1.31 
1.97 
1.10-1.56 
1.44-2.69 
RU athletes v Controls C–C/T–A 
*CC–CC 
1.32 
2.11 
1.11-1.59 
1.53-2.91 
Forwards v Controls C–C/T–A 
*CC–CC 
1.31 
2.19 
1.05-1.62 
1.51-3.16 
Backs v Controls C–C/T–A 
*CC–CC 
1.36 
1.86 
1.07-1.72 
1.29-2.67 
Back 3 and centres v 
Controls 
C–C/T–A 
*CC–CC 
1.49 
2.35 
1.12-1.99 
1.47-3.77 
*MDR best model versus all other genotype combinations for rs12722 and rs3196378. 
†All odds ratios were statistically significant (P < 0.05). 
